TCS has been named a leader in the Everest Group PEAK Matrix™ for Life Sciences Digital Services. The report analyzed the digital services capabilities of 23 IT service providers to the life sciences sector globally. It highlights TCS’ digital transformation capabilities with scale and consistency of performance. Further, the report cited as a key strength the company’s focus on next-generation digital solutions such as Advanced Drug Development (ADD) and Connected Clinical Trials (CCT), leveraging artificial intelligence (AI), smart analytics and IoT for drug development and patient engagement.
“Technologies such as AI and IoT are transforming the drug discovery and development value chain and helping life sciences companies accelerate their product innovation,” said Debashis Ghosh, Business Group Head, Life Sciences and Healthcare, TCS. “Our consistent leadership positioning in various analyst assessments is a reflection of our vision, capability, innovation efforts and the resultant market success.”
“Challenges such as the complexity and high cost of drug development and increased time-to-market for drugs confront life sciences enterprises today. Additionally, the expectations from life sciences firms to advance the value-based care conversation is amplifying the focus on outcome-based contracting. To overcome these challenges, enterprises are prioritizing the adoption of digital technologies with a focus on scaling technology proliferation and core business outcomes. With its Machine First Delivery Model™ and its Business 4.0™ framework, TCS provides a structured approach to digital transformation, led by a focus on core products, innovation labs, and creative engagement models to help scale innovation,” said Nitish Mittal, Vice President, Everest Group.